ES2751457T3 - Glucocorticoides altamente potentes - Google Patents
Glucocorticoides altamente potentes Download PDFInfo
- Publication number
- ES2751457T3 ES2751457T3 ES14849674T ES14849674T ES2751457T3 ES 2751457 T3 ES2751457 T3 ES 2751457T3 ES 14849674 T ES14849674 T ES 14849674T ES 14849674 T ES14849674 T ES 14849674T ES 2751457 T3 ES2751457 T3 ES 2751457T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- group
- dex
- alkyl
- cortisol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QXWJCVMEACMPQS-RTKAMITOSA-N CCNC(Nc(cc1)ccc1-[n]1ncc(C2)c1C=C(CCC1C(CC3)[C@](C)(C4)C3(C(NCc3ccccc3)=O)OC(c3ccc[o]3)=O)[C@@]2(C)C1[C@H]4O)=O Chemical compound CCNC(Nc(cc1)ccc1-[n]1ncc(C2)c1C=C(CCC1C(CC3)[C@](C)(C4)C3(C(NCc3ccccc3)=O)OC(c3ccc[o]3)=O)[C@@]2(C)C1[C@H]4O)=O QXWJCVMEACMPQS-RTKAMITOSA-N 0.000 description 1
- WOUIWWKLGPOWBN-MXDDREMYSA-N CCNCNc1cccc(-[n]2ncc(C3)c2C=C(CCC2C(CC4)[C@](C)(C5)[C@]4(C(NCc4ccccc4)=O)OC(c4ccc[o]4)=O)[C@@]3(C)C2[C@H]5O)c1 Chemical compound CCNCNc1cccc(-[n]2ncc(C3)c2C=C(CCC2C(CC4)[C@](C)(C5)[C@]4(C(NCc4ccccc4)=O)OC(c4ccc[o]4)=O)[C@@]3(C)C2[C@H]5O)c1 WOUIWWKLGPOWBN-MXDDREMYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0047—Nitrogen only at position 2(3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361882444P | 2013-09-25 | 2013-09-25 | |
| PCT/US2014/057497 WO2015048316A1 (en) | 2013-09-25 | 2014-09-25 | Highly potent glucocorticoids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2751457T3 true ES2751457T3 (es) | 2020-03-31 |
Family
ID=52744465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14849674T Active ES2751457T3 (es) | 2013-09-25 | 2014-09-25 | Glucocorticoides altamente potentes |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9975918B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3049089B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2016531852A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20160060688A (cg-RX-API-DMAC10.html) |
| CN (2) | CN113845558A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2014324961A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2751457T3 (cg-RX-API-DMAC10.html) |
| HK (1) | HK1222565A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2015048316A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3319611T (pt) | 2015-07-06 | 2021-04-22 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| DK3812392T3 (da) | 2015-07-06 | 2025-07-21 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| US10954265B2 (en) | 2016-10-14 | 2021-03-23 | Van Andel Research Institute | Structures and mechanism for the design of highly potent glucocorticoids |
| DK3529257T3 (da) | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| KR102521573B1 (ko) | 2016-10-18 | 2023-04-14 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| WO2021138540A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
| CN117024499A (zh) * | 2023-07-17 | 2023-11-10 | 陕西汉江药业集团股份有限公司 | 在2位引入亚甲基羟基的甾体化合物制备方法 |
| WO2025157225A1 (zh) * | 2024-01-24 | 2025-07-31 | 浙江柏拉阿图医药科技有限公司 | 一种高效力糖皮质激素化合物及其制备和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4049813A (en) | 1976-07-15 | 1977-09-20 | Sandoz, Inc. | Substituted isoxazolo pyridinones |
| WO2002102807A1 (en) | 2001-06-14 | 2002-12-27 | Banyu Pharmaceutical Co., Ltd. | Novel isoxazolopyridone derivatives and use thereof |
| GB0119911D0 (en) | 2001-08-15 | 2001-10-10 | Novartis Ag | Organic Compounds |
| MX2010003698A (es) | 2007-10-04 | 2010-04-21 | Astrazeneca Ab | Compuestos de [3,2-c]pirazol esteroides con actividad glucocorticoide. |
| US8173670B2 (en) * | 2009-01-13 | 2012-05-08 | Van Andel Research Institute | Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids |
| UY32523A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticosteroides |
| UY32525A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticosteroides |
| TW201111392A (en) * | 2009-06-16 | 2011-04-01 | Schering Corp | Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof |
-
2014
- 2014-09-25 HK HK16110801.0A patent/HK1222565A1/zh unknown
- 2014-09-25 CN CN202110799536.4A patent/CN113845558A/zh active Pending
- 2014-09-25 ES ES14849674T patent/ES2751457T3/es active Active
- 2014-09-25 CN CN201480063706.0A patent/CN105744937A/zh active Pending
- 2014-09-25 AU AU2014324961A patent/AU2014324961A1/en not_active Abandoned
- 2014-09-25 EP EP14849674.8A patent/EP3049089B1/en active Active
- 2014-09-25 WO PCT/US2014/057497 patent/WO2015048316A1/en not_active Ceased
- 2014-09-25 US US15/024,496 patent/US9975918B2/en active Active
- 2014-09-25 KR KR1020167010304A patent/KR20160060688A/ko not_active Withdrawn
- 2014-09-25 JP JP2016516578A patent/JP2016531852A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3049089A4 (en) | 2017-08-09 |
| US20160251393A1 (en) | 2016-09-01 |
| AU2014324961A8 (en) | 2016-04-21 |
| EP3049089A1 (en) | 2016-08-03 |
| AU2014324961A1 (en) | 2016-04-14 |
| CN113845558A (zh) | 2021-12-28 |
| HK1222565A1 (zh) | 2017-07-07 |
| CN105744937A (zh) | 2016-07-06 |
| US9975918B2 (en) | 2018-05-22 |
| EP3049089B1 (en) | 2019-08-21 |
| JP2016531852A (ja) | 2016-10-13 |
| WO2015048316A1 (en) | 2015-04-02 |
| KR20160060688A (ko) | 2016-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3049089B1 (en) | Highly potent glucocorticoids | |
| JP6700263B2 (ja) | エロビキシバットの結晶変態 | |
| CN102803203B (zh) | 卤代烷基杂芳基苯甲酰胺化合物 | |
| CA3154608A1 (en) | Il-17a modulators and uses thereof | |
| TW201632541A (zh) | 免疫調節劑 | |
| CN104211626A (zh) | 新型维生素d受体活化剂及制造方法 | |
| AU2023316546A1 (en) | Antibody-drug conjugate and use thereof | |
| TW202327620A (zh) | 一種抗炎症的化合物及其用途 | |
| ES2866698T3 (es) | Derivados de Aureobasidina y métodos de síntesis | |
| ES2945983T3 (es) | Glucocorticoides muy potentes | |
| CN118076623A (zh) | 大环免疫调节剂 | |
| WO2025157225A1 (zh) | 一种高效力糖皮质激素化合物及其制备和用途 | |
| HK40070300A (en) | Highly potent glucocorticoids | |
| JP2025533996A (ja) | シアノ置換含有ポリペプチド系化合物の結晶及びその製造方法 | |
| AU765476B2 (en) | Cyclooxygenase inhibitor | |
| HK40017057A (en) | Structures and mechanism for the design of highly potent glucocorticoids | |
| HK40017057B (en) | Structures and mechanism for the design of highly potent glucocorticoids | |
| CN117940445A (zh) | 大环免疫调节剂 | |
| BRPI0615670A2 (pt) | composição de liberação prolongada, formulação multiparticulada, e, uso de uma composição e do composto | |
| TW201121961A (en) | Aminothiazole derivatives | |
| JP2026501619A (ja) | 薬学的活性化合物、組成物、およびペンドリン調節方法 | |
| WO2025090466A1 (en) | Highly potent kappa opioid receptor agonists and method of use thereof | |
| TW202416975A (zh) | 萘并呋喃取代的戊二醯亞胺類化合物的晶型、製備方法及其應用 | |
| JP2009517424A (ja) | スルファモイルスルホネートプロドラッグ | |
| CN118632691A (zh) | Irhom2抑制剂及其用途 |